Christina Shafer - 05 May 2026 Form 4 Insider Report for Neurogene Inc. (NGNE)

Reporting relationship: Chief Commercial Officer
Issuer ticker: NGNE
Reported as of: 05 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 May 2026, 12:35:29 UTC
Prior SEC filing: 20 Apr 2026
Source filing: View source filing
Reporting owner signature: Donna M. Cochener, Attorney-in-Fact for Christina Shafer

Key filing fact

Christina Shafer filed Form 4 for Neurogene Inc. (NGNE) on 07 May 2026.

Key facts

This page summarizes Christina Shafer's Form 4 filing for Neurogene Inc. (NGNE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 May 2026, 12:35.

Change

Previous filing in this sequence was filed on 20 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001934412 Primary reporting owner

Shafer Christina

Relationship: Chief Commercial Officer
Address: 535 W 24TH STREET, 5TH FLOOR, NEW YORK
Signature: Donna M. Cochener, Attorney-in-Fact for Christina Shafer
Signature date: 07 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NGNE transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +120,000
Change %
Price: $0.000000^*
Shares after: 120,000
Date: 05 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 120,000
Exercise price: $28.94
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents the right to purchase 120,000 shares of the Issuer's common stock, one quarter of which will vest on April 20, 2027 with the remaining three quarters vesting on the 20th of each month in equal monthly installments through April 20, 2030, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.